CSL Limited (CSL)
CSL Limited develops, manufactures and markets human and veterinary pharmaceutical and diagnostic products derived from human plasma. The company markets its products - human and animal vaccines, antibiotics and anticoagulants – nationally and internationally. Recently the company has acquired Telecris in the US subject to regulatory approval. The Company is engaged in the research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. The Company operates in three segments: CSL Behring, Intellectual Property Licensing and Other Human Health. CSL Behring manufactures markets and develops plasma products. Intellectual Property Licensing includes revenue and associated expenses from the licensing of Intellectual Property generated by the Group to unrelated third parties. Other Human Health consists of CSL Bio plasma and CSL Biotherapies. These businesses manufacture and distribute bio therapeutic products. It operates in four geographic areas: Australia, the United States of America, Switzerland, and Germany. Its subsidiaries include CSL Employee Share Trust, CSL Biotherapies Pty Ltd, Cervax Pty Ltd, CSL Biotherapies (NZ) Limited, Iscotec AB, Zenyth Therapeutics Pty Ltd, CSL International Pty Ltd and CSL Finance Pty Ltd.